JP2025513384A - ヘパラン硫酸の蓄積を伴う疾患の処置のためのイミノ糖を含む治療用組成物 - Google Patents

ヘパラン硫酸の蓄積を伴う疾患の処置のためのイミノ糖を含む治療用組成物 Download PDF

Info

Publication number
JP2025513384A
JP2025513384A JP2024561909A JP2024561909A JP2025513384A JP 2025513384 A JP2025513384 A JP 2025513384A JP 2024561909 A JP2024561909 A JP 2024561909A JP 2024561909 A JP2024561909 A JP 2024561909A JP 2025513384 A JP2025513384 A JP 2025513384A
Authority
JP
Japan
Prior art keywords
iminosugars
treatment
accumulation
disease
mps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513384A5 (enExample
Inventor
パヴォーネ，ルイージ・ミケーレ
グアラグーナ，アンナリーザ
デ・パスクァーレ，ヴァレーリア
エスポージト，アンナ
ダゴスティーノ，マッシモ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D'agostino Massimo
De Pasquale Valeria
Esposito Anna
Guaragna Annalisa
Original Assignee
D'agostino Massimo
De Pasquale Valeria
Esposito Anna
Guaragna Annalisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D'agostino Massimo, De Pasquale Valeria, Esposito Anna, Guaragna Annalisa filed Critical D'agostino Massimo
Publication of JP2025513384A publication Critical patent/JP2025513384A/ja
Publication of JP2025513384A5 publication Critical patent/JP2025513384A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024561909A 2022-04-20 2023-04-18 ヘパラン硫酸の蓄積を伴う疾患の処置のためのイミノ糖を含む治療用組成物 Pending JP2025513384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102022000007808A IT202200007808A1 (it) 2022-04-20 2022-04-20 Composizioni terapeutiche per malattie causate da accumulo di eparan solfato
IT102022000007808 2022-04-20
PCT/EP2023/059966 WO2023203004A1 (en) 2022-04-20 2023-04-18 Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate

Publications (2)

Publication Number Publication Date
JP2025513384A true JP2025513384A (ja) 2025-04-24
JP2025513384A5 JP2025513384A5 (enExample) 2026-04-20

Family

ID=82483266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561909A Pending JP2025513384A (ja) 2022-04-20 2023-04-18 ヘパラン硫酸の蓄積を伴う疾患の処置のためのイミノ糖を含む治療用組成物

Country Status (9)

Country Link
US (1) US20250255856A1 (enExample)
EP (1) EP4511032A1 (enExample)
JP (1) JP2025513384A (enExample)
CN (1) CN119136803A (enExample)
AU (1) AU2023257557A1 (enExample)
CA (1) CA3249619A1 (enExample)
IT (1) IT202200007808A1 (enExample)
MX (1) MX2024012934A (enExample)
WO (1) WO2023203004A1 (enExample)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083205C1 (ru) 1994-01-19 1997-07-10 Товарищество с ограниченной ответственностью предприятие "БИОМ" Способ лечения мукополисахаридоза
RU2196988C2 (ru) 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002241853A1 (en) 2001-01-12 2002-07-24 Oxford Glycosciences (Uk) Ltd. Mucopolysaccharidosis therapies
JP2003265196A (ja) 2002-03-15 2003-09-24 Seikagaku Kogyo Co Ltd ムコ多糖症のスクリーニング方法
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
KR100762945B1 (ko) 2004-09-08 2007-10-04 진동규 동물 세포주를 이용한 이듀로네이트-설파타제의 발현 방법및 그 발현을 위한 세포주
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US8105788B2 (en) 2005-12-08 2012-01-31 The University Of British Columbia Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith
US20070161074A1 (en) 2005-12-27 2007-07-12 Daiichi Pharmaceutical Co., Ltd. Diagnostic method of mucopolysaccharidoses
KR101497194B1 (ko) * 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
AU2010366066B2 (en) 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
WO2012177778A1 (en) 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
HK1221871A1 (zh) * 2013-05-02 2017-06-16 The Chancellor, Masters And Scholars Of The University Of Oxford 使用亚氨基糖进行的糖脂抑制
WO2017201030A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating viral infection

Also Published As

Publication number Publication date
AU2023257557A1 (en) 2024-12-05
IT202200007808A1 (it) 2023-10-20
MX2024012934A (es) 2024-12-06
CN119136803A (zh) 2024-12-13
EP4511032A1 (en) 2025-02-26
CA3249619A1 (en) 2023-10-26
US20250255856A1 (en) 2025-08-14
WO2023203004A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US20230321130A1 (en) Senolytic Compositions and Uses Thereof
US10590082B2 (en) N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
EP1656373B1 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur utilisation en tant qu'antagonistes des chimiokines
JP2007502861A (ja) 抗菌方法及び組成物
JP2020037578A (ja) プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用
CN105682655A (zh) 抗微生物化合物
US20180312482A1 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
JP2022502486A (ja) 細菌感染の処置における使用のためのインダン誘導体
CN119136803A (zh) 用于治疗硫酸乙酰肝素蓄积疾病的治疗组合物
KR102946349B1 (ko) 신경퇴행성 질환의 치료약물 및 그의 응용
CN103965193B (zh) N-(苯氧烷基)咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
AU2019217292B2 (en) Novel compound for preventing or treating neurodegenerative disease and application thereof
WO2024013690A1 (en) 1,3,4-oxadiazole triazole compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
EP3978506A1 (en) Antibacterial aminoglycoside derivatives
JP2021520412A (ja) タンパク質ミスフォールディング疾患のための療法
RU2791317C2 (ru) Новая композиция для предупреждения или лечения нейродегенеративного расстройства и ее применение
WO2024180464A1 (en) Oxadiazole derivative compounds, and the pharmaceutical composition comprising the same
EA045519B1 (ru) Антибактериальные производные аминогликозидов
HK40072348A (en) Antibacterial aminoglycoside derivatives
JPH0733664A (ja) 平滑筋細胞増殖抑制剤
JPWO2008050600A1 (ja) 酸化ストレス性細胞死を分子背景とする難治性疾患の治療または予防剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250319

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260410